WATERTOWN, Mass.--(BUSINESS WIRE)--Panacos Pharmaceuticals, Inc. (NASDAQ:PANC), today announced factors that predict treatment response to bevirimat, a novel, oral HIV maturation inhibitor. The findings were described during multiple presentations at the 17th International HIV Drug Resistance Workshop in Sitges, Spain, considered the leading conference on HIV drug resistance. Aggregate data from Panacos’ recent Phase 2b clinical study in heavily treatment-experienced patients demonstrated that functional monotherapy with bevirimat resulted in a mean viral load reduction of 1.26 log10 in patients who had these response predictors and a threshold bevirimat concentration of 20 ug/mL.
